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Available online 25 November 2013Enzyme-linked immunosorbent assay (ELISA) is a validated and sensitive method for detection
of human autoantibodies, but may have problems with specificity. Non-specific binding is a
well-known problem often observed in tests for autoantibodies, when sera are incubated on
plastic surfaces, e.g. an ELISA plate. To understand the mechanisms underlying non-specific
immunoglobulin deposition, we here analyse the phenomenon in detail and we propose
means of reducing false positive test results caused by non-specific binding.
The level of non-specific binding, in sera with suspected autoreactivity, was analysed in non-coated
and autoantigen-coated ELISA wells and 4–32% of sera showed a high level of non-specific binding
depending on the assay conditions and serumproperties. Non-specifically binding serawere found to
contain increased concentrations of IgG and other inflammatory mediators. Moreover, non-specific
binding could be induced in serum by increasing the concentration of IgG and incubating the serum
at 40 °C. This suggests that non-specific binding immunoglobulins can be formed during
inflammation with high immunoglobulin levels and elevated temperature. We show that the level
of non-specific binding correlateswith the IgG concentration and therefore propose that non-specific
binding may be interpreted as an informative finding indicative of elevated IgG and inflammation.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license.Keywords:
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1.1. Autoantibody-based diagnostics and ELISA
Both cellular and humoral immunity can be involved in
autoimmune diseases and autoantibodies found in body fluids
can be used as a tool for correct diagnosis (Voller et al., 1976).
If autoimmunity is suspected, patient sera should be screened
for autoantibodies, for example using indirect immunofluo-
rescence, determining reactivity towards antigens in the used
tissue/cell preparation. If a vasculitis disease is suspected,
antibodies directed against neutrophil granules are tradition-
ally screened for by indirect immunofluorescence and quan-
tified using ELISA plates coated with the neutrophil proteins
myeloperoxidase (MPO) and proteinase 3 (PR3) (Cohen
Tervaert and Damoiseaux, 2012; Schultz and Tozman, 1995).NC-SA license.
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suspected, antibodies to Ro52, Ro60 and La are of diagnostic
value in addition to DNA antibodies (Hernandez-Molina et al.,
2011; Moutsopoulos and Zerva, 1990). If anti-phospholipid
syndrome is under consideration, cardiolipin or more specif-
ically β2 glycoprotein I (β2GP1) antibodies should be
determined (Shovman et al., 2007; Meroni et al., 2011).
1.2. ELISA and non-speciﬁc binding
ELISA is a high throughput, practical method and has been
used for several decades for analysis of human antibodies
(Engvall and Perlmann, 1971; van Weemen and Schuurs,
1971). However, ELISA may have problems with specificity
(Reen, 1994; Butler, 2000), and non-specific deposition of
immunoglobulins can lead to false positive results and
ultimately a wrong diagnosis and treatment.
False positive results can be caused by different phenom-
ena. These include inadequate blocking, where immunoglob-
ulins may adsorb directly to the polystyrene surface, and
binding of antibodies to the blocking agent(s) (Jørgensen et
al., 2005; Peterfi and Kocsis, 2000; Xiao and Isaacs, 2012).
Bovine serum albumin (BSA) and milk proteins are routinely
used as blocking agents and antibodies directed against these
proteins may cause false positive results (Andersen et al.,
2004; Willman et al., 1999). Non-specific binding has also
been ascribed to heterophile antibodies and anti-animal
antibodies have been described to interfere with specific
ELISA systems (Kaplan and Levinson, 1999; Levinson, 1992;
Levinson and Miller, 2002; Kricka, 1999). In capture ELISAs
rheumatoid factors (RFs) may pose a major problem since
they can bind antibodies and thereby obstruct the detection
of specific antibodies (Lewis et al., 2003). Also, antibodies
against complement components may cause false positive
results, as the polystyrene surface activates the complement
system, generating neoisotopes targeted by antibodies as
seen for C3 nephritis factor (Andersson et al., 2002; Nilsson et
al., 1993). In a similar manner immune complexes (ICs) may
be drawn to the surface, resulting in false positivity (Kricka,
1999; Hu et al., 1992; McFarlane et al., 1990).
1.3. Aim of this study
In this study, we evaluated the occurrence of non-specific
binding of sera in the autoantibody ELISAs mentioned above,
characterised the phenomenon of non-specific deposition of
immunoglobulins and evaluated the different steps of the
ELISAs to reduce the level of non-specific binding.
2. Materials and methods
2.1. Chemicals and buffers
Alkaline phosphatase (AP) substrate buffer (1 M ethanol-
amine, 0.5 mMMgCl2, pH 9.8), incubation buffer (0.05 M Tris,
0.15 M NaCl, 0.2% BSA, 0.05% polysorbate 20, 0.02% sodium
azide, 0.001% phenole red, pH 7.5), washing buffer (0.154 M
NaCl, 10 mM Tris, 0.005% Tween 20, pH 7.5), and carbonate
buffer (0.05 M sodium carbonate, pH 9.6). IVIg, calf serum and
rabbit serum were from Statens Serum Institut (Copenhagen,
Denmark). BSA, ovalbumin, AP-conjugated secondaryantibodies (goat anti-human IgG, IgM, IgA), protein G and
AP-substrate tablets were from Sigma-Aldrich (St. Louis,
Missouri, USA). Skimmed milk powder and polysorbate 20
(tween 20) were fromMerck (Darmstad, Germany).2.2. Sera
Control sera were obtained from healthy volunteers and
used anonymously. Normal human serum (NHS) was used as
a pool of 10 sera.
Sera observed to exhibit non-specific binding in MPO/PR3/
Ro/La/β2GP1 autoantibodies analyses were obtained from the
routine diagnostic laboratories at the Department of Clinical
Biochemistry, Immunology and Genetics, Statens Serum
Institut. Altogether, 847 sera submitted for 1707 autoantibody
tests were used. In Table 1, relative non-specific binding sera
(sticky sera) were defined as sera where IgG deposition on a
non-coated ELISA well exceeded the cut-off level for the
analysis (N10 units/ml). For other tables and figures absolute
non-specific bindingwas defined as absorbance readings above
0.2 absorbance units full scale (AUFS) (A405/650), with NHS
values below 0.2 AUFS (A405/650). Sera with a positive
serologic profile for bacterial antibodies were obtained from
the Department of Microbiological Diagnostics and Virology,
Statens Serum Institut. Selection criteria were a positive
antibody response for the indicated bacteria.2.3. IC assay
Sera were analysed for ICs using CirculatingIC-C1q
MicroVue™ kit from Quidel (Sissach, Switzerland), following
the recommendations from the manufacturer.2.4. Preparation of heat-induced IC
ICs were made by heating IVIg for 10 min at 56 or 60 °C.
In some experiments, IVIg was heated for different times at
different temperatures to investigate the time and temper-
ature profile for induction of non-specifically binding Igs.2.5. ELISA
Maxisorp microtitre plates were incubated with carbon-
ate buffer overnight at 2–6 °C or 2 h at room temperature.
Blocking of residual binding sites was performed using
washing buffer for 30 min at room temperature. Antibodies
against human IgG, IgM or IgA were diluted to 1:5000 in
incubation buffer and added in duplicates and incubated for
1 h at room temperature. Following 3× washing, the plate
was incubated with AP-conjugated secondary antibody
diluted 2000-fold in incubation buffer. After incubation for
1 h and extensive washing, bound antibodies were quanti-
fied by addition of pNPP (1 mg/ml) dissolved in AP substrate
buffer. The colour development was measured after incuba-
tion at room temperature for 30 min at 405 nm with
background subtraction at 650 nm as reference. Data are
presented as mean values of double determinations with
error bars indicating the standard deviation.
Table 1
Non-specific immunoglobulin deposition. 847 sera submitted for autoantibody tests (1707 tests in all) in the routine laboratory at Statens Serum Institut were
analysed for non-specific immunoglobulin binding to non-coated ELISA wells. Results are presented as number of serum samples and percent (of total serum
samples or non-specific binding sera). Non-specific binding sera were defined as sera with immunoglobulin deposition on a non-coated, blocked well above
cut-off.
Antigen Total number
of analyses
Positive for
antigen
Number of sera with non-specific
binding (% of total)
Antigen positive sera of non-specific binders
(% of non-specific binders)
False positives
(% of total)
MPO (IgG) 184 86 10 (5.4%) 3 (30.0%) 7 (3.8)
PR3 (IgG) 309 119 11 (3.6%) 3 (27.3%) 8 (2.6)
Ro52 (IgG) 322 70 35 (10.9%) 3 (8.6%) 32 (9.9)
Ro60 (IgG) 322 83 91 (28.3%) 8 (8.8%) 83 (25.8)
La (IgG) 322 20 12 (3.7%) 1 (8.3%) 11 (3.4)
β2gp1 (IgG) 124 36 40 (32.3%) 4 (10.0%) 36 (29.0)
β2gp1 (IgM) 124 33 33 (26.6%) 5 (15.2%) 28 (22.6)
Total 1707 447 232 (13.6%) 27 (11.6%) 205 (12.0)
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The antigen of interest was coated on a polystyrene
surface (Maxisorp) overnight in Phosphate-Buffered Saline
(β2GP1), 7 M urea (Ro52, Ro60, La), carbonate buffer (MPO)
or carbonate buffer with 0.01% Triton X-100 (PR3). After
coating, the ELISA wells were washed 3 times prior to
addition of serum (diluted 1:100 in incubation buffer) for
1 h. After incubation and washing, AP-conjugated goat
antibodies directed against human IgG or IgM were allowed
to bind for 60 min and quantified using pNPP for 30 min. All
diagnostic ELISAs used standard sera from which cut-off
levels and units were calculated. In Table 1 relative non-
specific binding is defined as absorbance values of a non-
coated well above the cut-off. To allow comparison of the
sera, absolute nonspecific binding was defined as absorbance
values above 0.2 AUFS (A405-650) after 30 min of incubation
with pNPP.
2.7. Detection of complement component 3 (C3) nephritic factor
Analyses for C3 nephritic factor were performed by
Labmedicin Skåne, Klinisk immunologi och transfusionsmedicin,
enheden för immunologi (Lund, Sweden).
2.8. Quantiﬁcation of C3 and immunoglobulins
The concentration of C3 and immunoglobulins was
measured by rate nephelometry on an Immage instrument
(Beckman Coulter, Fullerton, USA) using kits from Beckman
Coulter, Fullerton, USA and following the instructions of the
manufacturer.
2.9. Quantiﬁcation of C-reactive protein (CRP)
The serum concentration of CRP was analysed using
Time-Resolved Amplified.
Cryptate Emission (TRACE) technology on a Kryptor
(BRAHMS AG, Hennigsdorf, Germany) according to the
instructions from the manufacturer.
2.10. Statistical analysis
Student's t-test was performed using Graphpad Prism (La
Jolla, CA, USA).3. Results
3.1. Non-speciﬁc binding in solid phase autoantibody assays
In routine testing for PR3/MPO antibodies it was consis-
tently observed that some sera tested positive for both PR3
and MPO antibodies, while being negative in immunofluo-
rescence tests for neutrophil granulocyte antibodies. For this
reason, we developed ELISA assays which systematically
screen all sera for non-specific binding using antigen-coated
and non-coated wells for all samples. Using these assays, we
evaluated 309 sera submitted for PR3 antibody testing and
184 sera submitted for MPO antibody testing (Table 1).
Among the samples tested for PR3 antibodies, 119 (39%)
tested clearly positive, eight samples showed relative
non-specific binding (levels of IgG deposition to non-coated
ELISA wells above cut-off) and were negative for specific
antibodies (3%), three sera (1%) showed relative non-specific
binding but were still PR3 antibody-positive after subtraction
of relative non-specific binding. Altogether, approximately
4% of the sera exhibited non-specific binding in the PR3
antibody assay and approximately the 3% were false posi-
tives. In the MPO antibody assay, 47% of the 184 sera were
found to be positive, 98 were negative, seven (4%) were
negative with non-specific binding and three sera (2%) with
non-specific binding were positive. Collectively, 5% of the
serum samples submitted for MPO autoantibody testing were
observed to exhibit non-specific binding and 4% were false
positives (Table 1).
Of 322 serum samples, which were analysed for Ro52,
Ro60 and La autoantibodies, 22%, 26% and 6% were found to
be positive for Ro52, Ro60 and La autoantibodies, respective-
ly, and 35 (11%), 91 (28%) and 12 (4%) sera exhibited relative
non-specific binding in these assays. Of the 35 non-specific
binding sera found in the Ro52 assay, three were positive
whereas eight of the 91 non-specific binding sera in the Ro60
assay were autoantibody positive and one of the 12 sera
with relative non-specific binding tested positive in the La
autoantibody assay (Table 1). Thus, the number of false
positive results varied from 3 to 29%.
Non-specific binding was also analysed in a β2GP1
antibody assay where 124 sera were analysed for both IgG
and IgM autoantibodies. 27% of these sera were IgM
autoantibody positive and 29% were IgG autoantibody
positive. Forty (32%) and thirty-three (27%) sera in the
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non-specific binding was measured using three different blocking condi-
tions: 2% skimmed milk, 2% bovine serum albumin (BSA), or 2% polysorbate
20 for 30 min using seven sera with non-specific binding and a control
serum pool (NHS — normal human serum). B) The level of non-specific
binding in eight sera (four with non-specific binding, four without) was
measured using a number of different additives to the Tris incubation buffer
(1% polysorbate 20, skimmed milk, Triton X-100, calf serum, bovine serum
albumin (BSA), rabbit serum and ovalbumin. The following steps of the
ELISA procedure were performed as described in Materials and methods.
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analysed for deposition of IgG and IgM, respectively. 10% of
the sera showing relative non-specific binding in the β2GP1
IgG assay were autoantibody positive and 15% in the β2GP1
IgM assay with relative non-specific binding were autoanti-
body positive.
Overall, the extent of relative non-specific binding varied
from 4 to 32% of the analysed sera (3–29% false positives)
and is thus a significant threat to correct serodiagnostics
(Table 1). Due to this significant percentage of sera showing
non-specific binding we sought to investigate the cause of
antigen-independent immunoglobulin deposition of some
sera and to evaluate the ELISA setup to minimize interference
with specific autoantibody detection.3.2. Characterization of non-speciﬁc binding
We first wished to characterise the non-specific binding.
The dependency on incubation time and concentration (serum
dilution) was therefore determined for five non-specific
binding sera (Fig. 1A and results not shown). Increasing
deposition of IgG was observed with increasing incubation
time until 90–120 min, where the binding reached a maxi-
mum. The non-specific binding was observed to decrease as a
function of serum dilution but with individual dilution curves
for the 5 sera presented (Fig. 1A).The non-specific binding was further investigated by
analysing the effect of increasing concentrations of salt and
detergent (Fig. 1B and results not shown). The analysed sera
were highly sensitive to increasing concentrations of sodium
chloride in the incubation buffer and the non-specific binding
decreased when the salt concentration was increased. For
one serum, the non-specific binding to non-coated wells was
reduced with 40%, when the salt concentration was increased
from 0.15 M to 0.35 M (Fig. 1B). Increasing the detergent
concentration had some inhibitory effect on the non-specific
binding, but this effect was highly serum dependent. Only
two of the four sera tested were markedly affected (15–30%)
in their ability to deposit IgG on a non-coated surface, when
the detergent concentration was increased from 0.06 to 1%
polysorbate 20 (results not shown).
3.3. Inﬂuence of immuno-assay design
Several causes of non-specific binding have previously been
proposed. Insufficient blocking could be an obvious problem
causing non-specific binding (Peterfi and Kocsis, 2000;
Jørgensen et al., 2005; Xiao and Isaacs, 2012), however an
increased blocking step (blocking the wells for 1 h with
1% polysorbate 20) was not found to reduce the non-specific
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Fig. 4. Non-specific binding can be induced by heating and may be caused by
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treatment (60 °C for 10 min). The level of non-specific binding was analysed
on non-coated ELISA wells as described in Materials and methods.
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shown). Another possible hypothesis of non-specific binding
is antibodies directed against blocking proteins. As the blocking
solutionmay contain BSA, skimmedmilk or detergent, blocking
agent-directed antibodies could cause non-specific binding.
Seven samples showing non-specific binding and a control
serum pool (NHS) were tested for IgG deposition on a BSA-,
skimmed milk-, or polysorbate 20-coated surface (Fig. 2A). In
the tested sera, no or only a little increase in non-specific
binding was observed on the BSA surface compared to the
detergent-blocked surface, suggesting few BSA-directed anti-
bodies whereas increased IgG deposition was found on the
skimmed milk surface for five out of seven sera.
We hypothesised that if the polystyrene surface of the ELISA
well had the ability to deposit IgG, then preincubation on a
polystyrene surface may adsorb the IgG prone for deposition
and prevent non-specific binding to an antigen-coated surface.
We tested this hypothesis by pre-incubating non-specific
binding sera in uncoated ELISA wells for 1 h prior to transfer
of the sera to another uncoated, but blocked, well. This
pretreatment was found to reduce the non-specific binding,
but not to abolish it completely (results not shown).
If non-specific binding antibodies are of low affinity, the
presence of competing agents during serum incubation might
remove or diminish non-specific binding. We therefore added
1% of the following agents to the 50 mMTris incubation buffer:
BSA, skimmed milk, ovalbumin, rabbit serum, calf serum,
polysorbate 20, or Triton X-100, and found that skimmed milk
and ovalbumin were good additives to remove non-specific
binding but that ovalbumin also induced non-specific binding
in some NHS samples (Fig. 2B).
The influence of the conjugate specificity was also investi-
gated, showing that secondary antibodies directed against the
whole IgG molecule, gamma chain or kappa chain all detected
specific as well as non-specific binding (results not shown).
A majority of autoantibodies with a diagnostic value are of
the IgG class and most non-specific binding detected is
therefore of IgG class although non-specific IgM deposition
can also be observed (as seen in the β2GP1 assay, Table 1).
Non-specific binding of the individual Ig classes was investi-
gated in ELISA plates. The immunoglobulin deposition of
individual sera was analysed using 16 sera with non-specific
IgG deposition. In many of these, non-specific IgM deposition
was observed and in several sera, non-specific deposition of IgA
could be detected showing that non-specific immunoglobulin
deposition often occurs with several isotypes (Fig. 3).
3.4. ICs induce non-speciﬁc binding
ICs have been proposed to cause non-specific binding (Hu
et al., 1992; Jethwa et al., 2000). The occurrence of ICs in
patient sera showing non-specific binding was therefore
assessed, which showed that only a proportion of non-
specific binding sera contained measurable, C1q-binding ICs
(Fig. 4A). Of 16 sera showing non-specific binding, 50% were
found to contain circulating ICs, measured by C1q interaction.
Circulating ICs are therefore a possible inducer of non-Fig. 3. Subtypes of interfering immunoglobulins. Sixteen sera showing non-specific
analysed for the type of deposited immunoglobulins using AP-conjugated secondar
cut-off (0.2 absorbance units full scale).specific binding although a major part of non-specific binding
cannot be explained by C1q-binding circulating ICs. No
correlation was observed between the level of non-specific
binding and measurable ICs.
Artificial, heat-induced ICs were added to normal human
serum and shown to induce non-specific binding (Fig. 4B). The
induction of immune aggregates was investigated adding IVIg
in different concentrations to NHS with or without heating
(60 °C, 10 min), showing the induction of non-specific binding
to be dependent on heat induction, increasing with increasingbinding were incubated in non-coated, detergent-blocked ELISA wells and
y antibodies specific for human IgG, IgM or IgA. Stippled line represents IgG
32 E. Güven et al. / Journal of Immunological Methods 403 (2014) 26–36immunoglobulin concentration (Fig. 4C). Similar results were
obtained with individual sera (results not shown).
3.5. Inﬂammatory parameters correlate with non-speciﬁc binding
In order to further characterise the sera with high non-
specific binding in ELISA, we determined immunoglobulin,
C3 and CRP concentrations of 11 sera showing non-specific
binding (Table 2 and Fig. 5). It was seen that sera with high
non-specific binding had higher levels of total IgG compared
with NHS pools not showing non-specific binding (Fig. 5A,
P b 0.05). On the average, total IgG concentrations were
17.9 ± 6.5 mg/ml (mean ± SD) compared to the control
group of 10.7 ± 2.3 mg/ml (mean ± SD), and nine of the 11
tested sera with non-specific binding had IgG concentration
above the normal range.
Also, IgA levels were higher in five of 11 serum samples
showing non-specific binding, whereas IgM concentrations
were in the normal range or slightly decreased. All of the 11
sera showing non-specific binding, showed increased immu-
noglobulin levels of either IgG or IgA type (Table 2).
CRP concentrations were also assessed in the sera showing
non-specific binding, with an average CRP concentration that
was 10 times higher than the controls (54.9 ± 60.79 compared
to 4.7 ± 6.6 mg/l, P b 0.05) (Fig. 5B). In conclusion, elevated
IgG, elevated IgA, elevated CRP or a combination of these could
be observed in all the serum samples with non-specific binding
(Table 2).
In order to investigate if increased immunoglobulin levels
were the cause of non-specific binding, sera with non-specific
binding and increased IgG concentration were diluted to
10 mg IgG/ml and compared with NHS (9.1 ± 1.6 mg/ml
IgG) but non-specific binding to a non-coated surface could
still be observed in the diluted sera (Fig. 5C), showing that
non-specific binding is not solely dependent on immuno-
globulin concentration.
3.6. Non-speciﬁc binding can occur in sera with recent or
on-going infection
We speculated that non-specific binding could be a
general trait of inflammation/infection and 70 sera withTable 2
Inflammatory markers in non-specific binding sera. 11 sera with non-specific bindin
the concentration of C-reactive protein (CRP) and complement component 3 (C3). N
surface. A * represents low non-specific binding (0.2 b A405 b 0.3), two ** represe
high non-specific binding (A405 N 0.5). The reference intervals are shown in bracket
sera without non-specific binding were analysed and the analysed serum compone
Year of birth Non-specific
binding
IgG
(6.4–13.5 g/l)
IgA
(0.70–3.12 g
1985 * 14.7 3.04
1926 * 13.8 4.78
1943 * 12.9 6.35
1928 * 11.9 4.15
1988 * 21.3 1.66
1941 ** 15.2 4.94
1956 ** 32.6 2.15
1945 ** 26.8 2.49
1974 *** 15.8 2.84
1936 *** 15.9 6.06
1930 *** 20.0 3.54antibodies to different bacteria were assessed for non-
specific deposition of IgG on a non-coated surface (Table 3).
The results showed that non-specific IgG deposition could
be found in a number of sera with recent or ongoing
bacterial infections (Table 3). Non-specific binding was
most pronounced in sera positive for antibodies against
Bordetella pertussis, Treponema pallidum and Salmonella
enteritidis/typhimurium, where 8/10, 7/10 and 5/10 samples
showed non-specific binding, respectively. We therefore
collected 10 new serum samples with a high positive
antibody titre for these bacteria and analysed the level of
absolute non-specific binding and the immunoglobulin
concentration, confirming that non-specific binding sera
had elevated IgG concentrations and showing a correlation
between immunoglobulin concentration and level of
non-specific binding (Fig. 6). We realized that part of the
serum samples had actually been heat treated (56 °C for
30 min, to inactivate complement) prior to analysis for
antibodies against T. pallidum and prior to detection of
non-specific binding. A third collection of 44 new samples
without heat treatment was therefore collected and
analysed. Only one serum showed intense non-specific
binding whereas the 43 serum samples showed little or no
non-specific binding (AUFS b 0.3) (Fig. 7). The serum
samples were heated at 40 °C overnight or at 56 °C for
30 min showing that non-specific binding was induced
(Fig. 7A) and that the level of non-specific binding
correlated with serum IgG concentration after heat treat-
ment (Fig. 7B).
Repeated freezing/thawing of sera (−20 °C or−80 °C or
−135 °C for 1–10 cycles) did not induce non-specific
binding (results not-shown).
3.7. Non-speciﬁc binding can be induced in NHS
As elevated immunoglobulin concentrations were found
in sera with non-specific binding and since non-specific
binding could be induced in NHS by heat treatment, we
analysed if non-specific binding could be induced under
conditions that approached the physiological conditions
found in patients with systemic autoimmune diseases or
infections. IVIg was added to NHS (without non-specificg in the MPO/PR3 ELISA were analysed for IgG-, IgA- and IgM-concentration,
on-specific binding was defined as IgG deposition on a blocked, non-coated
nt medium non-specific binding (0.3 b A405 b 0.5) and three *** represent
s and values outside the reference interval are shown in bold. Also, 11 control
nts were inside the reference intervals (not shown in the table).
/l)
IgM
(0.56–3.52 g/l)
CRP
(0–10 mg/l)
C3
(0.79–1.52 g/l)
1.54 2 1.21
0.44 58 1.93
1.40 17 1.88
2.74 102 1.68
0.75 58 0.349
0.43 84 1.55
0.70 195 0.50
2.55 7 1.69
1.22 6 1.97
1.53 9 1.28
1.78 2 1.82
no
n-
sp
ec
ific
 bi
nd
ing
 se
ra
 
NH
S
0
10
20
30
40
Ig
G
 c
on
ce
nt
ra
tio
n 
(m
g/m
l)
no
n-
sp
ec
ific
 bi
nd
ing
 se
ra
NH
S
0
50
100
150
200
250
CR
P 
co
nc
en
tra
tio
n 
(m
g/l
)
P=0.002
P=0.009
A
B
C
1 2 3 4
0
1
2
3
non-specific binders
diluted non-specific binders
Ab
so
rb
an
ce
 (4
05
 n
m
)
Fig. 5. Inflammatory markers in sera with non-specific binding. The con-
centration of IgG (A) and C-reactive protein (CRP) (B) was analysed in 11 sera
with non-specific binding and in 10 sera without non-specific binding using
rate nephelometry. P-values were calculated using a one-tailed student's t-test.
C) Four serawith elevated concentrations of IgG and a high level of non-specific
binding were diluted to the IgG concentration of normal human serum (NHS,
10 mg/ml) and the level of non-specific binding was compared to NHS
(stippled line) and undiluted non-specific binding sera.
Table 3
Non-specific binding in sera from patients with immunoglobulins directed
against the indicated infectious bacteria. Non-specific binding was defined
as IgG deposition on a non-coated, detergent-blocked ELISA well with AUFS
(A405/650) above 0.2.
Bacteria Number of
samples
Non-specific binding
sera (%)
Yersinia enterocolitica 10 30
Campylobacter jejuni 10 10
Salmonella enteritidis/typhimurium 10 50
Legionella pneumophila 10 40
Helicobacter pylori 10 20
Treponema palliduma 10 70
Bordetella pertussis 10 80
a Serum samples were heated to 56 °C for 30 min.
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Fig. 6. 30 serum samples positive for antibodies against Bordetella pertussis
(10 sera), Treponema palladium (10 sera) and Salmonella sp. (10 sera) were
analysed for the level of non-specific binding (x-axis) and IgG concentration
(y-axis). The level of non-specific binding and IgG concentration was found
to correlate with a slope of 8.0 ± 2.0 (R-square = 0.37, P = 0.004).
33E. Güven et al. / Journal of Immunological Methods 403 (2014) 26–36binding) and heated to slightly elevated temperatures (40 °C,
overnight). This revealed that non-specific binding increased
with increasing concentration of IgG (Fig. 8).4. Discussion
4.1. Non-speciﬁc binding and false positive ELISA results
False positive ELISA results are a major problem in the
detection of human specific immunoglobulins.We assessed the
extent of the problem by analysing 847 sera for non-specific
immunoglobulin deposition on a non-coated surface. Overall,
4–32% of the sera showed relative non-specific binding,
depending on the assay. Non-specific binding is thus a
significant problem and should be addressed in all routine
laboratories measuring human (auto)antibodies.
The non-specific immunoglobulin deposition was found
to be dependent on the assay conditions and we evaluated
the individual steps of the ELISA setup in order to minimize
the level of non-specific binding.
4.2. The effect of blocking agents
We found that insufficient blocking of the ELISA plate
could cause non-specific binding and that antibodies directed
against the blocking agent (most commonly BSA and
skimmed milk) could result in false positive results. Previous
studies have indicated a high level of BSA antibodies in sera
from some blood donors and patients suffering from systemic
autoimmune diseases (Jørgensen et al., 2005). Skimmed milk
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Fig. 7. Induction of nonspecific binding in patient sera. The level of non-specific binding was analysed in 44 serum samples with antibodies to bacteria before and
after heating to 40 °C overnight or 56 °C for 30 min (A) and the level of non-specific binding was compared to IgG concentration (B).
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Fig. 8. Non-specific binding can be induced in NHS. Non-specific binding in
NHS with elevated IgG concentration is dependent on IgG concentration.
IVIg was added to NHS to elevate total IgG concentration to the indicated
concentration and incubated at 40 °C for 24 h. Nonspecific IgG deposition
was determined using the ELISA setup described in Materials and methods.
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sera from individuals with milk antibodies may cause
immunoglobulin deposition.
As polysorbate 20 was found to block ELISA wells with
equal efficiency as the used protein blocking agents, deter-
gent blocking was preferred over protein blocking. A number
of supplementations were also assessed for their ability to
inhibit non-specific binding in the incubation buffer. 1% of
detergent (polysorbate 20/Triton X-100), animal sera (calf/
rabbit), purified protein (ovalbumin/BSA) and skimmed milk
were compared as buffer additives. Non-specific IgG binding
could be markedly suppressed, especially using 1% skimmed
milk or 1% ovalbumin. Ovalbumin however, also induced
some non-specific binding in the control sera, possibly as a
result of ovalbumin/anti-ovalbumin complex formation.
Skimmed milk reduced the non-specific binding approxi-
mately 50% without increasing non-specific binding in
control sera. Also, sera were diluted and pre-incubated on a
35E. Güven et al. / Journal of Immunological Methods 403 (2014) 26–36non-coated surface and this was also found to decrease the
non-specific binding.4.3. The effect of the conjugate
The IgG deposition was confirmed using different
AP-conjugated secondary antibodies directed against whole
IgG, gamma chain or kappa chain showing that non-specific
binding was not caused by binding of the secondary
antibody (results not shown). IgG deposition was also
confirmed using AP-conjugated protein G, ruling out the
possibility of interfering anti-animal antibodies (Kricka,
1999).4.4. The role of immune-complexes and Ig concentration
ICs are known to deposit non-specifically on polystyrene
surfaces, and we observed that some but not all sera with
non-specific binding (four out of 16 sera) contained C1q-
binding ICs. ICs were prepared and added to a serum not
showing non-specific IgG deposition. Addition of ICswas found
to induce non-specific binding in a concentration-dependent
manner. We also measured the concentration of IgG, IgA and
IgM in 11 serum samples with non-specific binding showing
that all had increased immunoglobulin concentrations. Nine
out of 11 had increased IgG concentration; six out of 11 had
increased IgA levels, whereas all samples had IgM concentra-
tions in the normal range or below.4.5. Non-speciﬁc binding and inﬂammatory parameters
CRP concentrations were found to be markedly increased
together with immunoglobulins. Elevated IgG concentrations
are seen in systemic autoimmune diseases, but elevated IgG
levels are also observed in infections, lymphoproliferative
disorders and non-haematological malignancies (Dispenzieri
et al., 2001). 70 serum samples from patients with recent
or ongoing bacterial infections (antibody positive) were
analysed, showing that 43% showed non-specific binding.
We analysed additional 30 sera with suspected infectious
background for non-specific binding and immunoglobulin
concentration showing a correlation between IgG concentra-
tion and non-specific binding. Immunoglobulin concentra-
tion in itself was, however, not found to be the only cause of
non-specific binding as non-specific binding sera with
elevated IgG still showed non-specific binding after dilution
to the level of NHS (10 mg/ml). Some of the serum samples
positive for bacterial antibodies had been heat-treated to
56 °C and 44 new samples without prior heat treatment was
analysed for non-specific deposition of IgG. 43 of 44 samples
showed initially little non-specific binding but the non-
specific could be heat-induced and the level of non-specific
binding was dependent on the IgG concentration. This
suggests that elevated post sampling temperatures may
cause massive problems for nonspecific binding. Also, IgG
was added to NHS without non-specific binding showing
that increased immunoglobulin concentration alone was not
sufficient to induce non-specific binding.4.6. The effect of temperature
Since non-specific binding sera were observed to contain
elevated levels of immunoglobulins and since non-specific
binding could be induced by heat-aggregated IVIg, we investi-
gated if the IgG modification needed to induce non-specific
binding could occur under physiological conditions or condi-
tions occurring in sera preanalytically but after sampling. IVIg
was added to NHS and the immunoglobulin-spiked serum was
treated with temperatures found in the body under fever or
experienced during transport or storage of sera (40 °C), where
it was observed to induce non-specific binding dependent
on IgG concentration. This experiment thereby provided an
explanation for the non-specific binding observed, suggesting
that conformational alterations occur in immunoglobulins at
high concentrations and under elevated temperatures (either
elevated body temperature or elevated temperature for the
blood sample pre-analytically).4.7. Conclusion
ELISA can quantify minute amounts of antibodies present
in serum. However, ELISA holds some problems with regard
to specificity and false positive results may occur, causing
autoantigen-negative sera with non-specific binding to be
interpreted as antigen-positive (Cole et al., 1999; Despres
and Grant, 1998). Non-specific binding can be quantified
using non-coated, blocked wells and the signal can be
subtracted from the antigen-specific signal before the
presence of autoantibodies is reported. Also, alternative
methods (e.g. indirect immunofluorescence or immunoblots)
can in many cases be used to confirm ELISA results. Elevated
levels of immunoglobulins have previously been observed in
sera showing false positive test results in ELISA systems
(McFarlane et al., 1990; Cowchock et al., 1988).
In conclusion, we found increased levels of immunoglob-
ulins (IgG, IgA) in samples showing non-specific binding and
we propose that non-specific binding occurs in serum
samples with elevated immunoglobulin concentration ex-
posed to elevated temperatures. We suggest that all sera
tested for antigen-specific antibodies in solid phase immu-
noassays should also be analysed for non-specific binding
immunoglobulins, which may be formed in vivo during fever
or in vitro upon storage at too high temperature.Acknowledgements
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